Phathom Pharmaceuticals, Inc.
For the period ended Jun 30, 2026. Filed Jul 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 30, 2026
PHAT$5.45+2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Product revenue, net | $74,274 | $39,503 | $132,575 | $68,023 |
| Cost of revenue | 15,096 | 5,038 | 27,091 | 8,762 |
| Gross profit | 59,178 | 34,465 | 105,484 | 59,261 |
| Operating expenses: | ||||
| Research and development | 7,813 | 9,076 | 15,585 | 18,260 |
| Selling, general and administrative | 55,330 | 85,313 | 109,341 | 179,787 |
| Total operating expenses | 63,143 | 94,389 | 124,926 | 198,047 |
| Loss from operations | (3,965) | (59,924) | (19,442) | (138,786) |
| Other (expense) income: | ||||
| Interest income | 1,510 | 1,787 | 3,246 | 4,427 |
| Interest expense | (15,103) | (17,518) | (30,900) | (35,588) |
| Other expense, net | (24) | (155) | (855) | (179) |
| Total other expense | (13,617) | (15,886) | (28,509) | (31,340) |
| Net loss and comprehensive loss | $(17,582) | $(75,810) | $(47,951) | $(170,126) |
| Net loss per share, basic and diluted | $(0.21) | $(1.05) | $(0.58) | $(2.36) |
| Weighted-average shares of common stock outstanding, basic and diluted | 83,747,104 | 72,466,203 | 82,903,547 | 72,219,179 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.